A High-Content Screening (HCS) Assay for the Identification of Chemical Inducers of PML Oncogenic Domains (PODs)

PML is a multi-functional protein with roles in tumor suppression and host defense against viruses. When active, PML localizes to subnuclear structures named PML oncogenic domains (PODs) or PML nuclear bodies (PML-NBs), whereas inactive PML is located diffusely throughout the nucleus of cells. The objective of the current study was to develop a high content screening (HCS) assay for the identification of chemical activators of PML. We describe methods for automated analysis of POD formation using high throughput microscopy (HTM) to localize PML immunofluorescence in conjunction with image analysis software for POD quantification. Using this HCS assay in 384 well format, we performed pilot screens of a small synthetic chemical library and mixture-based combinatorial libraries, demonstrating the robust performance of the assay. HCS counter-screening assays were also developed for hit characterization, based on immunofluorescence analyses of the subcellular location of phosphorylated H2AX or phosphorylated CHK1, which increase in a punctate nuclear pattern in response to DNA damage. Thus, the HCS assay devised here represents a high throughput screen that can be utilized to discover POD-inducing compounds that may restore the tumor suppressor activity of PML in cancers or possibly promote anti-viral states.

[1]  P. Salomoni,et al.  Daxx: death or survival protein? , 2006, Trends in cell biology.

[2]  P. Freemont,et al.  PML protein isoforms and the RBCC/TRIM motif , 2001, Oncogene.

[3]  Pier Paolo Pandolfi,et al.  The Role of PML in Tumor Suppression , 2002, Cell.

[4]  Clemencia Pinilla,et al.  Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. , 2008, Journal of combinatorial chemistry.

[5]  P. Pandolfi,et al.  The function of PML in p 53-dependent apoptosis , 2000 .

[6]  P. Pandolfi,et al.  A role for PML and the nuclear body in genomic stability , 1999, Oncogene.

[7]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[8]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[9]  Jian-Hua Tong,et al.  Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML , 2010, Science.

[10]  Clemencia Pinilla,et al.  Mixture-Based Synthetic Combinatorial Libraries , 1999 .

[11]  T. Regad,et al.  Role and fate of PML nuclear bodies in response to interferon and viral infections , 2001, Oncogene.

[12]  S. Akira,et al.  ZIP Kinase Triggers Apoptosis from Nuclear PML Oncogenic Domains , 2003, Molecular and Cellular Biology.

[13]  P. Pandolfi,et al.  Pml is essential for multiple apoptotic pathways , 1998, Nature Genetics.

[14]  R. Davis,et al.  PML mediates IFN-α-induced apoptosis in myeloma by regulating TRAIL induction , 2005 .

[15]  Hyungtae Kim,et al.  PML-RARα Alleviates the Transcriptional Repression Mediated by Tumor Suppressor Rb* , 2001, The Journal of Biological Chemistry.

[16]  Ailan Guo,et al.  The function of PML in p53-dependent apoptosis , 2000, Nature Cell Biology.

[17]  John Calvin Reed,et al.  Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation. , 2008, Genes & development.

[18]  E. Bowman,et al.  UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML , 2003, Oncogene.

[19]  John Calvin Reed,et al.  Daxx represses expression of a subset of antiapoptotic genes regulated by nuclear factor-kappaB. , 2006, Cancer research.

[20]  P. Pandolfi,et al.  Promyelocytic Leukemia Protein (Pml) and Daxx Participate in a Novel Nuclear Pathway for Apoptosis , 2000, The Journal of experimental medicine.

[21]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[22]  R. Schreiber,et al.  Interferon-gamma and cancer immunoediting. , 2005, Immunologic research.

[23]  Sara L. Tuttle,et al.  The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. , 2005, Blood.

[24]  R A Houghten,et al.  Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. , 1992, BioTechniques.

[25]  Clemencia Pinilla,et al.  Advances in the use of synthetic combinatorial chemistry: Mixture-based libraries , 2003, Nature Medicine.

[26]  Z. Darżynkiewicz,et al.  Induction of ATM Activation, Histone H2AX Phosphorylation and Apoptosis by Etoposide: Relation to Cell Cycle Phase , 2007, Cell cycle.

[27]  J. Licht,et al.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. , 1999, Blood.

[28]  T. Hofmann,et al.  Body language: the function of PML nuclear bodies in apoptosis regulation , 2003, Cell Death and Differentiation.

[29]  Pier Paolo Pandolfi,et al.  The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network , 2008, Nature.

[30]  Pier Paolo Pandolfi,et al.  The mechanisms of PML-nuclear body formation. , 2006, Molecular cell.

[31]  Joe S. Mymryk,et al.  Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly , 2003, Journal of Cell Science.

[32]  Rosa Bernardi,et al.  Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies , 2007, Nature Reviews Molecular Cell Biology.

[33]  T. Gilliam,et al.  Differential SMN2 expression associated with SMA severity , 1998, Nature Genetics.

[34]  R. Schreiber,et al.  Interferon-γ and cancer immunoediting , 2005 .

[35]  R. Davis,et al.  PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. , 2005, Blood.

[36]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[37]  J. Berenson,et al.  Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. , 2006, Clinical lymphoma & myeloma.